How many biomarker measurements are needed to predict prognosis in Crohn's disease patients under infliximab?-A prospective study.

ABSTRACT:

Background

Timely stratification of Crohn's disease (CD) is essential for patients' management. The use of noninvasive accurate biomarkers is key to monitor treatment and to pursue mucosal healing, the ultimate treatment endpoint in CD.

Objective

We aimed to evaluate the performance of readily available biomarkers and develop risk matrices to predict CD progression.

Methods

Data from 289 CD patients receiving infliximab (IFX) maintenance therapy for 2 years was collected; those patients were included in DIRECT, a prospective multicenter observational study. Disease progression was evaluated using two composite outcomes incorporating clinical and drug-related factors, the first including IFX dose and/or frequency adjustments. Univariate and multivariable logistic regre

SUBMITTER: Magro F 

PROVIDER: S-EPMC10337732 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature